Pseudoprogression in a patient with metastatic melanoma treated with PD-1 and LAG-3 inhibition.

IF 1.5 4区医学 Q3 DERMATOLOGY

Melanoma Research Pub Date : 2024-04-18 DOI:10.1097/cmr.0000000000000974

Lawrence W Wu, Jacqueline J Tao, Diana McDonnell, Benjamin Izar

引用次数: 0

Abstract

Pseudoprogression encapsulates a process of temporary radiographic growth followed by subsequent regression of metastatic melanoma lesions in response to immune checkpoint blockade (ICB), such as the combination of anti-programmed cell death protein 1 (PD-1) and anticytotoxic T-lymphocyte-associated antigen 4 therapy. This occurs in approximately 5-10% of ICB-treated patients, but has not yet been described in the context of novel combination therapies. Here, we report a case of an 89-year-old patient with metastatic melanoma to the liver, lung and lymph nodes, who underwent treatment with Opdualag (combining anti-PD-1 nivolumab and anti-lymphocyte-activation gene 3 relatlimab ICBs), and developed pseudoprogression after two cycles of therapy. The patient experienced a radiographic increase in liver metastatic lesion size, but was found to have a subsequent reduction in these lesions. The patient has been on therapy for 18 months without evidence of disease progression and continues to be clinically well-appearing.

查看原文本刊更多论文

一名接受 PD-1 和 LAG-3 抑制剂治疗的转移性黑色素瘤患者出现假性进展。

假性进展是指转移性黑色素瘤病灶在接受免疫检查点阻断（ICB）治疗（如抗程序性细胞死亡蛋白1（PD-1）和抗细胞毒性T淋巴细胞相关抗原4的联合治疗）后，出现暂时的放射学生长，随后消退的过程。约有 5-10% 接受过 ICB 治疗的患者会出现这种情况，但在新型联合疗法的背景下还未出现过这种情况。在此，我们报告了一例 89 岁的肝脏、肺部和淋巴结转移性黑色素瘤患者，该患者接受了 Opdualag（结合抗 PD-1 nivolumab 和抗淋巴细胞活化基因 3 relatlimab 的 ICB）治疗，并在两个周期治疗后出现假性进展。该患者的肝转移病灶在影像学上有所增大，但随后发现这些病灶有所缩小。患者已经接受了 18 个月的治疗，没有出现疾病进展的迹象，临床表现仍然良好。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Melanoma Research 医学-皮肤病学

CiteScore

3.40

自引率

4.50%

发文量

139

审稿时长

6-12 weeks

期刊介绍： Melanoma Research is a well established international forum for the dissemination of new findings relating to melanoma. The aim of the Journal is to promote the level of informational exchange between those engaged in the field. Melanoma Research aims to encourage an informed and balanced view of experimental and clinical research and extend and stimulate communication and exchange of knowledge between investigators with differing areas of expertise. This will foster the development of translational research. The reporting of new clinical results and the effect and toxicity of new therapeutic agents and immunotherapy will be given emphasis by rapid publication of Short Communications. Thus, Melanoma Research seeks to present a coherent and up-to-date account of all aspects of investigations pertinent to melanoma. Consequently the scope of the Journal is broad, embracing the entire range of studies from fundamental and applied research in such subject areas as genetics, molecular biology, biochemistry, cell biology, photobiology, pathology, immunology, and advances in clinical oncology influencing the prevention, diagnosis and treatment of melanoma.